Evidence map›Paper›PMID 36075893›Full record

ArticleCell death & disease2022

Galectin-3 critically mediates the hepatoprotection conferred by M2-like macrophages in ACLF by inhibiting pyroptosis but not necroptosis signalling.

Li Bai, Wang Lu, Shan Tang, Huixin Tang, Manman Xu, Chen Liang, Sujun Zheng, Shuang Liu, Ming Kong, Zhongping Duan and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. [Exploring the protective effects and mechanisms of HYX1-derived exosomes on acute liver failure based on disulfidptosis signaling].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Protective innate immunity againstInfection and immunity · 2024
    Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Li Bai *The Fourth Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, 100069, Beijing, China.
Wang Lu *The Fourth Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, 100069, Beijing, China.
Shan TangThe First Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, 100069, Beijing, China.
Huixin TangThe Fourth Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, 100069, Beijing, China.
Manman XuThe Fourth Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, 100069, Beijing, China.
Chen LiangThe First Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, 100069, Beijing, China.
Sujun ZhengThe First Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, 100069, Beijing, China.
Shuang LiuThe Fourth Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, 100069, Beijing, China.
Ming KongThe Fourth Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, 100069, Beijing, China.
Zhongping DuanThe Fourth Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, 100069, Beijing, China.
Yu ChenThe Fourth Department of Hepatology, Beijing YouAn Hospital, Capital Medical University, 100069, Beijing, China. chybeyond1071@ccmu.edu.cn.ORCID 0000-0002-6759-7978
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously documented that M2-like macrophages exert a hepatoprotective effect in acute-on-chronic liver failure (ACLF) by inhibiting necroptosis signalling. Nevertheless, the molecular mechanism behind this hepatoprotection still needs to be further dissected. Galectin-3 (GAL3) has been reported to be critically involved in the pathogenesis of multiple liver diseases, whereas the potential role of GAL3 in ACLF remains to be explored. Herein, we hypothesised that GAL3 plays a pivotal role in the hepatoprotection conferred by M2-like macrophages in ACLF by inhibiting necroptosis. To test this hypothesis, we first assessed the expression of GAL3 in control and fibrotic mice with or without acute insult. Second, loss- and gain-of-function experiments of GAL3 were performed. Third, the correlation between GAL3 and M2-like macrophage activation was analysed, and the potential role of GAL3 in M2-like macrophage-conferred hepatoprotection was confirmed. Finally, the molecular mechanism underlying GAL3-mediated hepatoprotection was dissected. GAL3 was found to be obviously upregulated in fibrotic mice with or without acute insult but not in acutely injured mice. Depletion of GAL3 aggravated hepatic damage in fibrotic mice upon insult. Conversely, adoptive transfer of GAL3 provided normal mice enhanced resistance against acute insult. The expression of GAL3 is closely correlated with M2-like macrophage activation. Through adoptive transfer and depletion experiments, M2-like macrophages were verified to act as a major source of GAL3. Importantly, GAL3 was confirmed to hold a pivotal place in the hepatoprotection conferred by M2-like macrophages through loss- and gain-of-function experiments. Unexpectedly, the depletion and adoptive transfer of GAL3 resulted in significant differences in the expression levels of pyroptosis but not necroptosis signalling molecules. Taken together, GAL3 plays a pivotal role in the hepatoprotection conferred by M2-like macrophages in ACLF by inhibiting pyroptosis but not necroptosis signalling. Our findings provide novel insights into the pathogenesis and therapy of ACLF.

Indexed as

Acute-On-Chronic Liver FailureGalectin 3AnimalsMacrophage ActivationMacrophagesMicePyroptosisGalectin 3

Identifiers

PMID36075893
PMCPMC9458748
OpenAlexW4294944229

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.